Clinical predictors of cognitive function in adults treated with hematopoietic cell transplantation

Cancer

Volumn 118, Issue 13, 2012, Pages 3407-3416

  Jim, Heather S L ^a   Small, Brent ^b   Hartman, Sheri ^c   Franzen, Jamie ^d   Millay, Shannon ^e   Phillips, Kristin ^a   Jacobsen, Paul B ^a   Booth Jones, Margaret ^a   Pidala, Joseph ^a  

^a H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^b UNIVERSITY OF SOUTH FLORIDA   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d UNIVERSITY OF SOUTH FLORIDA   (United States)

^e INDIANA STATE DEPARTMENT OF HEALTH   (United States)

Author keywords

Bone marrow transplantation; Hematopoietic stem cell transplantation; Neoplasms; Neurobehavioral manifestations

Indexed keywords

ANTINEOPLASTIC AGENT; NARCOTIC AGENT; STEROID;

ADULT; AGED; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; BRAIN FUNCTION; CANCER CHEMOTHERAPY; CANCER PATIENT; COGNITIVE DEFECT; CONTROLLED STUDY; DISEASE SEVERITY; ENTERITIS; FEMALE; FUNCTIONAL ASSESSMENT; GRAFT VERSUS HOST REACTION; HEMATOLOGIC DISEASE; HEMATOLOGIC MALIGNANCY; HUMAN; HUMAN CELL; LENGTH OF STAY; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; MEMORY; MENTAL PERFORMANCE; MUCOSA INFLAMMATION; NEUROPSYCHOLOGICAL TEST; OUTCOME ASSESSMENT; PREDICTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; RISK FACTOR; SKULL IRRADIATION; TASK PERFORMANCE; THERAPY EFFECT;

ADULT; COGNITION; COGNITION DISORDERS; CRANIAL IRRADIATION; EXECUTIVE FUNCTION; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; MALE; MEMORY; MIDDLE AGED; NEOPLASMS; NEUROPSYCHOLOGICAL TESTS; RISK FACTORS;

EID: 84862571465     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.26645     Document Type: Article

References (48)

1. Serna DS, Lee SJ, Zhang MJ, et al. Trends in survival rates after allogeneic hematopoietic stem-cell transplantation for acute and chronic leukemia by ethnicity in the United States and Canada. J Clin Oncol. 2003; 21: 3754-3760. (Pubitemid 46606229)
2. Rizzo JD, Wingard JR, Tichelli A, et al. Recommended screening and preventive practices for long-term survivors after hematopoietic cell transplantation: joint recommendations of the European Group for Blood and Marrow Transplantation, Center for International Blood and Marrow Transplant Research, and the American Society for Blood and Marrow Transplantation (EBMT/CIBMTR/ASBMT). Bone Marrow Transplant. 2006; 37: 249-261.
3. Andrykowski MA, Bishop MM, Hahn EA, et al. Long-term health-related quality of life, growth, and spiritual well-being after hematopoietic stem-cell transplantation. J Clin Oncol. 2005; 23: 599-608. (Pubitemid 46224238)
4. Bevans MF, Marden S, Leidy NK, et al. Health-related quality of life in patients receiving reduced-intensity conditioning allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant. 2006; 38: 101-109.
5. Byar KL, Eilers JE, Nuss SL,. Quality of life 5 or more years post-autologous hematopoietic stem cell transplant. Cancer Nurs. 2005; 28: 148-157. (Pubitemid 40489239)
6. Ahles TA, Saykin A,. Cognitive effects of standard-dose chemotherapy in patients with cancer. Cancer Invest. 2001; 19: 812-820. (Pubitemid 33151212)
7. Ahles TA, Saykin AJ, Noll WW, et al. The relationship of APOE genotype to neuropsychological performance in long-term cancer survivors treated with standard dose chemotherapy. Psychooncology. 2003; 12: 612-619. (Pubitemid 37086736)
8. Fliessbach K, Helmstaedter C, Urbach H, et al. Neuropsychological outcome after chemotherapy for primary CNS lymphoma: a prospective study. Neurology. 2005; 64: 1184-1188.
9. de Brabander C, Cornelissen J, Smitt PA, Vecht CJ, van den Bent MJ,. Increased incidence of neurological complications in patients receiving an allogenic bone marrow transplantation from alternative donors. J Neurol Neurosurg Psychiatry. 2000; 68: 36-40. (Pubitemid 30248656)
10. Fann JR, Alfano CM, Roth-Roemer S, Katon WJ, Syrjala KL,. Impact of delirium on cognition, distress, and health-related quality of life after hematopoietic stem-cell transplantation. J Clin Oncol. 2007; 25: 1223-1231. (Pubitemid 46640568)
11. Beglinger LJ, Duff K, Van Der Heiden S, et al. Neuropsychological and psychiatric functioning pre- and posthematopoietic stem cell transplantation in adult cancer patients: a preliminary study. J Int Neuropsychol Soc. 2007; 13: 172-177. (Pubitemid 46487388)
12. Syrjala KL, Dikmen S, Langer SL, Roth-Roemer S, Abrams JR,. Neuropsychologic changes from before transplantation to 1 year in patients receiving myeloablative allogeneic hematopoietic cell transplant. Blood. 2004; 104: 3386-3392. (Pubitemid 39507163)
13. Syrjala KL, Artherholt SB, Kurland BF, et al. Prospective neurocognitive function over 5 years after allogeneic hematopoietic cell transplantation for cancer survivors compared with matched controls at 5 years. J Clin Oncol. 2011; 29: 2397-2404.
14. Jacobs SR, Small BJ, Booth-Jones M, Jacobsen PB, Fields KK,. Changes in cognitive functioning in the year after hematopoietic stem cell transplantation. Cancer. 2007; 110: 1560-1567. (Pubitemid 47463071)
15. Booth-Jones M, Jacobsen PB, Ransom S, Soety E,. Characteristics and correlates of cognitive functioning following bone marrow transplantation. Bone Marrow Transplant. 2005; 36: 695-702. (Pubitemid 41518712)
16. Harder H, Duivenvoorden HJ, van Gool AR, Cornelissen JJ, van den Bent MJ,. Neurocognitive functions and quality of life in haematological patients receiving haematopoietic stem cell grafts: a 1-year follow-up pilot study. J Clin Exp Neuropsychol. 2006; 28: 283-293.
17. Meyers CA, Weitzner M, Byrne K, Valentine A, Champlin RE, Przepiorka D,. Evaluation of the neurobehavioral functioning of patients before, during, and after bone marrow transplantation. J Clin Oncol. 1994; 12: 820-826. (Pubitemid 24110924)
18. Sostak P, Padovan CS, Yousry TA, Ledderose G, Kolb HJ, Straube A,. Prospective evaluation of neurological complications after allogeneic bone marrow transplantation. Neurology. 2003; 60: 842-848. (Pubitemid 36297371)
19. Harder H, Van Gool AR, Cornelissen JJ, et al. Assessment of pre-treatment cognitive performance in adult bone marrow or haematopoietic stem cell transplantation patients: a comparative study. Eur J Cancer. 2005; 41: 1007-1016. (Pubitemid 40602852)
20. Schulz-Kindermann F, Mehnert A, Scherwath A, et al. Cognitive function in the acute course of allogeneic hematopoietic stem cell transplantation for hematological malignancies. Bone Marrow Transplant. 2007; 39: 789-799. (Pubitemid 46901978)
21. Correa DD, DeAngelis LM, Shi W, Thaler H, Glass A, Abrey LE,. Cognitive functions in survivors of primary central nervous system lymphoma. Neurology. 2004; 62: 548-555. (Pubitemid 38252794)
22. Andrykowski MA, Schmitt FA, Gregg ME, Brady MJ, Lamb DG, Henslee-Downey PJ,. Neuropsychologic impairment in adult bone marrow transplant candidates. Cancer. 1992; 70: 2288-2297.
23. Harder H, Holtel H, Bromberg JE, et al. Cognitive status and quality of life after treatment for primary CNS lymphoma. Neurology. 2004; 62: 544-547. (Pubitemid 38252793)
24. Jansen CE, Miaskowski C, Dodd M, Dowling G, Kramer J,. A meta-analysis of studies of the effects of cancer chemotherapy on various domains of cognitive function. Cancer. 2005; 104: 2222-2233. (Pubitemid 41579970)
25. Padovan CS, Yousry TA, Schleuning M, Holler E, Kolb HJ, Straube A,. Neurological and neuroradiological findings in long-term survivors of allogeneic bone marrow transplantation. Ann Neurol. 1998; 43: 627-633. (Pubitemid 28225554)
26. Chapman SL, Byas-Smith MG, Reed BA,. Effects of intermediate- and long-term use of opioids on cognition in patients with chronic pain. Clin J Pain. 2002; 18 (4 suppl): S83-S90. (Pubitemid 34815398)
27. Pidala J, Anasetti C, Jim H,. Quality of life after allogeneic hematopoietic cell transplantation. Blood. 2009; 114: 7-19.
28. Schagen SB, van Dam FSAM, Muller MJ, Boogerd W, Lindeboom J, Bruning PF,. Cognitive deficits after postoperative adjuvant chemotherapy for breast carcinoma. Cancer. 1999; 85: 640-650. (Pubitemid 29075285)
29. Wieneke MH, Dienst ER,. Neuropsychological assessment of cognitive functioning following chemotherapy for breast cancer. Psychooncology. 1995; 4: 61-66. (Pubitemid 26093776)
30. van Dam FSAM, Schagen SB, Muller MJ, et al. Impairment of cognitive function in women receiving adjuvant treatment for high-risk breast cancer: high-dose versus standard-dose chemotherapy. J the Natl Cancer Inst. 1998; 90: 210-218. (Pubitemid 28114539)
31. Weschler D,. WAIS-III Administration and Scoring Manual. San Antonio, TX: Psychological Corporation; 1997.
32. Reitan RM, Wolfson D,. The Halstead-Reitan Neuropsychological Test Battery: Theory and Clinical Interpretation. Tucson, AZ: Neuropsychology Press; 1993.
33. Benton AL, Hamsher K,. Multilingual Aphasia Examination. Iowa City, IA: AJA Associates; 1989.
34. Trenarry MR, Crosson B, DeBoe J, Leber WR,. The Stroop Neuropsychological Screening Test. Lutz, FL: Psychological Assessment Resources; 1989.
35. Connors CK,. Connors' Continuous Performance Test 3.0. Toronto, Ontario, Canada: MHS; 2000.
36. Delis DC, Kramer JH, Kaplan E, Ober BA,. California Verbal Learning Test: Adult Version. San Antonio, TX: Psychological Corporation; 1987.
37. Weschler D,. Weschler Memory Scale-III Manual. San Antonio, TX: Psychological Corporation; 1997.
38. Matthews C, Klove H,. Instruction Manual for the Adult Neuropsychology Test Battery. Madison, WI: University of Wisconsin Medical School; 1964.
39. Heaton RK,. Comprehensive Norms for an Expanded Halstead-Reitan Battery: A suppl to the Wechsler Adult Intelligence Scales-Revised (WAIS-R). Lutz, FL: Psychological Assessment Resources; 1992.
40. Heaton RK, Grant I, Matthews CG,. Comprehensive Norms for an Expanded Halstead-Reitan Battery: Demographic Correction, Research Findings, and Clinical Application. Lutz, FL: Psychological Assessment Resources; 1991.
41. Spreen O, Strauss E,. A Compendium of Neuropsychological Tests: Administration, Norms, and Commentary. ed. 2nd. New York: Oxford University Press; 1998.
42. Hoffman L, Hofer SM, Sliwinski MJ,. On the confounds among retest gains and age-cohort differences in the estimation of within-person change in longitudinal studies: a simulation study [published online ahead of print May 30, 2011 ]. Psychol Aging. 2011.
43. Friedman MA, Fernandez M, Wefel JS, Myszka KA, Champlin RE, Meyers CA,. Course of cognitive decline in hematopoietic stem cell transplantation: a within-subjects design. Arch Clin Neuropsychol. 2009; 24: 689-698.
44. Cimprich B, Reuter-Lorenz P, Nelson J, et al. Prechemotherapy alterations in brain function in women with breast cancer. J Clin Exp Neuropsychol. 2010; 32: 324-331.
45. Ferguson RJ, McDonald BC, Saykin AJ, Ahles TA,. Brain structure and function differences in monozygotic twins: possible effects of breast cancer chemotherapy. J Clin Oncol. 2007; 25: 3866-3870. (Pubitemid 47477262)
46. Inagaki M, Yoshikawa E, Matsuoka Y, et al. Smaller regional volumes of brain gray and white matter demonstrated in breast cancer survivors exposed to adjuvant chemotherapy. Cancer. 2007; 109: 146-156. (Pubitemid 46120202)
47. Fliessbach K, Urbach H, Helmstaedter C, et al. Cognitive performance and magnetic resonance imaging findings after high-dose systemic and intraventricular chemotherapy for primary central nervous system lymphoma. Arch Neurol. 2003; 60: 563-568. (Pubitemid 36427970)
48. Ferguson RJ, Ahles TA, Saykin AJ, et al. Cognitive-behavioral management of chemotherapy-related cognitive change. Psychooncology. 2007; 16: 772-777. (Pubitemid 47249179)